BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 11830484)

  • 1. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.
    Gombart AF; Hofmann WK; Kawano S; Takeuchi S; Krug U; Kwok SH; Larsen RJ; Asou H; Miller CW; Hoelzer D; Koeffler HP
    Blood; 2002 Feb; 99(4):1332-40. PubMed ID: 11830484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
    Fuchs O; Provaznikova D; Kocova M; Kostecka A; Cvekova P; Neuwirtova R; Kobylka P; Cermak J; Brezinova J; Schwarz J; Markova J; Salaj P; Klamova H; Maaloufova J; Lemez P; Novakova L; Benesova K
    Blood Cells Mol Dis; 2008; 40(3):401-5. PubMed ID: 18182175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.
    Asou H; Gombart AF; Takeuchi S; Tanaka H; Tanioka M; Matsui H; Kimura A; Inaba T; Koeffler HP
    Genes Chromosomes Cancer; 2003 Feb; 36(2):167-74. PubMed ID: 12508245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
    Kato N; Kitaura J; Doki N; Komeno Y; Watanabe-Okochi N; Togami K; Nakahara F; Oki T; Enomoto Y; Fukuchi Y; Nakajima H; Harada Y; Harada H; Kitamura T
    Blood; 2011 Jan; 117(1):221-33. PubMed ID: 20884804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the C/EBPα C-terminal tail residues involved in the protein interaction with GABP and their potency in myeloid differentiation of K562 cells.
    Shimokawa T; Nunomura S; Fujisawa D; Ra C
    Biochim Biophys Acta; 2013 Nov; 1829(11):1207-17. PubMed ID: 24076158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm.
    Togami K; Kitaura J; Uchida T; Inoue D; Nishimura K; Kawabata KC; Nagase R; Horikawa S; Izawa K; Fukuyama T; Nakahara F; Oki T; Harada Y; Harada H; Aburatani H; Kitamura T
    Exp Hematol; 2015 Apr; 43(4):300-8.e1. PubMed ID: 25534203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML.
    Kaeferstein A; Krug U; Tiesmeier J; Aivado M; Faulhaber M; Stadler M; Krauter J; Germing U; Hofmann WK; Koeffler HP; Ganser A; Verbeek W
    Leukemia; 2003 Feb; 17(2):343-9. PubMed ID: 12592334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
    Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
    Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP.
    Wang SE; Wu FY; Fujimuro M; Zong J; Hayward SD; Hayward GS
    J Virol; 2003 Jan; 77(1):600-23. PubMed ID: 12477864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C/EBP-epsilon: chromosomal mapping and mutational analysis of the gene in leukemia and preleukemia.
    Koike M; Chumakov AM; Takeuchi S; Tasaka T; Yang R; Nakamaki T; Tsuruoka N; Koeffler HP
    Leuk Res; 1997 Sep; 21(9):833-9. PubMed ID: 9393598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C/EBPα dysregulation in AML and ALL.
    Paz-Priel I; Friedman A
    Crit Rev Oncog; 2011; 16(1-2):93-102. PubMed ID: 22150310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction.
    Rangatia J; Vangala RK; Singh SM; Peer Zada AA; Elsässer A; Kohlmann A; Haferlach T; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Jul; 22(30):4760-4. PubMed ID: 12879022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Meijer J; van Oosterhoud S; van Putten WL; Valk PJ; Berna Beverloo H; Tenen DG; Löwenberg B; Delwel R
    Hematol J; 2003; 4(1):31-40. PubMed ID: 12692518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.
    Tiesmeier J; Czwalinna A; Müller-Tidow C; Krauter J; Serve H; Heil G; Ganser A; Verbeek W
    Br J Haematol; 2003 Nov; 123(3):413-9. PubMed ID: 14616999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
    Harada H; Harada Y; Tanaka H; Kimura A; Inaba T
    Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
    Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis.
    Loomis KD; Zhu S; Yoon K; Johnson PF; Smart RC
    Cancer Res; 2007 Jul; 67(14):6768-76. PubMed ID: 17638888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
    Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
    Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.